Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia

Background: Lung cancer is the most common cause of cancer-related death among men in the world. Given the very high mortality caused by lung cancer, a biological marker to determine a more sensitive therapy among non-small cell lung cancer (NSCLC) patients is needed. This study aims to demonstrate...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-09, Vol.14 (9), p.e29386-e29386
Main Authors: Hanafi, Arif R, Jayusman, Achmad M, Sutandyo, Noorwati, Kurniawati, Sri, Setiawan, Lyana, Diandra, Alyssa, Hidayat, Kusmantoro
Format: Article
Language:English
Subjects:
Anemia
Antigens
Biomarkers
Cancer therapies
Creatinine
Electrolytes
Growth factors
Hemoglobin
Hyponatremia
Internal Medicine
Kinases
Laboratories
Lung cancer
Medical diagnosis
Medical prognosis
Medical records
Mortality
Mutation
Oncology
Pathology
Patients
Potassium
Pulmonology
Quality of life
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c276t-c9fe0fd83cf730aed20de0287a9dd6f38ede511c8d09252070d785d8038db8623
container_end_page e29386
container_issue 9
container_start_page e29386
container_title Curēus (Palo Alto, CA)
container_volume 14
creator Hanafi, Arif R
Jayusman, Achmad M
Sutandyo, Noorwati
Kurniawati, Sri
Setiawan, Lyana
Diandra, Alyssa
Hidayat, Kusmantoro
description Background: Lung cancer is the most common cause of cancer-related death among men in the world. Given the very high mortality caused by lung cancer, a biological marker to determine a more sensitive therapy among non-small cell lung cancer (NSCLC) patients is needed. This study aims to demonstrate that the clinical laboratory result can be a prognosis marker in NSCLC patients in Indonesia.Methods: This study was a retrospective cohort study. The sample was obtained from the patient's serum and the examined routine blood test (hemoglobin, leukocyte, platelets), hemostasis (fibrinogen and D-dimers), blood chemistry test (aspartate transaminase [AST], alanine transaminase [ALT], albumin, urea, creatinine, and blood glucose), electrolyte (sodium, potassium, chloride, and calcium) and tumor markers (carcinoembryonic antigen [CEA] and Cyfra 21-1). Data were analyzed and interpreted using SPSS (IBM Corp., Armonk, NY, USA). Analysis of the data was done to find the survival rate of sociodemographic variables, clinicopathologic variables, and clinic laboratory variables.Results: The study findings showed statistically significant results that were poor prognosis for these following conditions: performance status (PS) 3-4 median survival (MS):26 days, p=
doi_str_mv 10.7759/cureus.29386
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9585362</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2730312730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c276t-c9fe0fd83cf730aed20de0287a9dd6f38ede511c8d09252070d785d8038db8623</originalsourceid><addsrcrecordid>eNpdkVtLxDAQhYMoKOu--QMCvihYTRPbpC_CUrws1FW8PIdsMl2j3USTdmH_vd0Lor7MDMw3hzkchI5Scs55VlzoLkAXz2nBRL6DDmiai0Sk4nL317yPhjG-E0JSwinh5AB9lY11VqsGV2rqg2p9WOIniF3TRqwifgx-5ny0Ed-r8AEBW4dHZqGcBoOfWzUDPPEuiXPVNLiEvlSdm-FyBQR8Mnkuq_J0dTR2xjuIVh2ivVo1EYbbPkCvN9cv5V1SPdyOy1GVaMrzNtFFDaQ2gumaM6LAUGKAUMFVYUxeMwEGsjTVwpCCZiszhovMCMKEmYqcsgG62uh-dtM5GA2uDaqRn8HOVVhKr6z8u3H2Tc78QhaZyNha4GQrEPxXB7GVcxt1b1E58F2UtP-Lpes6QMf_0HffBdfbW1OXBcty3lNnG0oHH2OA-ueZlMhVhnKToVxnyL4ByfGQ0A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2730493567</pqid></control><display><type>article</type><title>Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Hanafi, Arif R ; Jayusman, Achmad M ; Sutandyo, Noorwati ; Kurniawati, Sri ; Setiawan, Lyana ; Diandra, Alyssa ; Hidayat, Kusmantoro</creator><creatorcontrib>Hanafi, Arif R ; Jayusman, Achmad M ; Sutandyo, Noorwati ; Kurniawati, Sri ; Setiawan, Lyana ; Diandra, Alyssa ; Hidayat, Kusmantoro</creatorcontrib><description>Background: Lung cancer is the most common cause of cancer-related death among men in the world. Given the very high mortality caused by lung cancer, a biological marker to determine a more sensitive therapy among non-small cell lung cancer (NSCLC) patients is needed. This study aims to demonstrate that the clinical laboratory result can be a prognosis marker in NSCLC patients in Indonesia.Methods: This study was a retrospective cohort study. The sample was obtained from the patient's serum and the examined routine blood test (hemoglobin, leukocyte, platelets), hemostasis (fibrinogen and D-dimers), blood chemistry test (aspartate transaminase [AST], alanine transaminase [ALT], albumin, urea, creatinine, and blood glucose), electrolyte (sodium, potassium, chloride, and calcium) and tumor markers (carcinoembryonic antigen [CEA] and Cyfra 21-1). Data were analyzed and interpreted using SPSS (IBM Corp., Armonk, NY, USA). Analysis of the data was done to find the survival rate of sociodemographic variables, clinicopathologic variables, and clinic laboratory variables.Results: The study findings showed statistically significant results that were poor prognosis for these following conditions: performance status (PS) 3-4 median survival (MS):26 days, p=&lt;0.001; TNM stage IVb MS:58 days, p=0.001; high leukocyte MS:69 days, p=0.018; low platelet MS:50 days, p=0.013; high D-dimer MS:69 days, p=0.020; low albumin MS:56 days, p=0.001; high sodium MS:15 days, low sodium MS:50 days, p=&lt;0.001; high chloride MS:15 days, low chloride MS:27 days, p=&lt;0.001.Conclusion: In the advanced stage NSCLC, these findings indicate poorer prognoses; PS 3-4, IVb clinical stage, leukocytosis, thrombocytopenia, hyper-coagulopathy, hypoalbuminemia, hyper-hyponatremia, and hyper-hypochloremia. Further studies regarding the correlation between clinical laboratory and survival rate are needed.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.29386</identifier><language>eng</language><publisher>Palo Alto: Cureus Inc</publisher><subject>Anemia ; Antigens ; Biomarkers ; Cancer therapies ; Creatinine ; Electrolytes ; Growth factors ; Hemoglobin ; Hyponatremia ; Internal Medicine ; Kinases ; Laboratories ; Lung cancer ; Medical diagnosis ; Medical prognosis ; Medical records ; Mortality ; Mutation ; Oncology ; Pathology ; Patients ; Potassium ; Pulmonology ; Quality of life ; Tumors</subject><ispartof>Curēus (Palo Alto, CA), 2022-09, Vol.14 (9), p.e29386-e29386</ispartof><rights>Copyright © 2022, Hanafi et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022, Hanafi et al. 2022 Hanafi et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c276t-c9fe0fd83cf730aed20de0287a9dd6f38ede511c8d09252070d785d8038db8623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2730493567/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2730493567?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids></links><search><creatorcontrib>Hanafi, Arif R</creatorcontrib><creatorcontrib>Jayusman, Achmad M</creatorcontrib><creatorcontrib>Sutandyo, Noorwati</creatorcontrib><creatorcontrib>Kurniawati, Sri</creatorcontrib><creatorcontrib>Setiawan, Lyana</creatorcontrib><creatorcontrib>Diandra, Alyssa</creatorcontrib><creatorcontrib>Hidayat, Kusmantoro</creatorcontrib><title>Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia</title><title>Curēus (Palo Alto, CA)</title><description>Background: Lung cancer is the most common cause of cancer-related death among men in the world. Given the very high mortality caused by lung cancer, a biological marker to determine a more sensitive therapy among non-small cell lung cancer (NSCLC) patients is needed. This study aims to demonstrate that the clinical laboratory result can be a prognosis marker in NSCLC patients in Indonesia.Methods: This study was a retrospective cohort study. The sample was obtained from the patient's serum and the examined routine blood test (hemoglobin, leukocyte, platelets), hemostasis (fibrinogen and D-dimers), blood chemistry test (aspartate transaminase [AST], alanine transaminase [ALT], albumin, urea, creatinine, and blood glucose), electrolyte (sodium, potassium, chloride, and calcium) and tumor markers (carcinoembryonic antigen [CEA] and Cyfra 21-1). Data were analyzed and interpreted using SPSS (IBM Corp., Armonk, NY, USA). Analysis of the data was done to find the survival rate of sociodemographic variables, clinicopathologic variables, and clinic laboratory variables.Results: The study findings showed statistically significant results that were poor prognosis for these following conditions: performance status (PS) 3-4 median survival (MS):26 days, p=&lt;0.001; TNM stage IVb MS:58 days, p=0.001; high leukocyte MS:69 days, p=0.018; low platelet MS:50 days, p=0.013; high D-dimer MS:69 days, p=0.020; low albumin MS:56 days, p=0.001; high sodium MS:15 days, low sodium MS:50 days, p=&lt;0.001; high chloride MS:15 days, low chloride MS:27 days, p=&lt;0.001.Conclusion: In the advanced stage NSCLC, these findings indicate poorer prognoses; PS 3-4, IVb clinical stage, leukocytosis, thrombocytopenia, hyper-coagulopathy, hypoalbuminemia, hyper-hyponatremia, and hyper-hypochloremia. Further studies regarding the correlation between clinical laboratory and survival rate are needed.</description><subject>Anemia</subject><subject>Antigens</subject><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Creatinine</subject><subject>Electrolytes</subject><subject>Growth factors</subject><subject>Hemoglobin</subject><subject>Hyponatremia</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Laboratories</subject><subject>Lung cancer</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>Medical records</subject><subject>Mortality</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Patients</subject><subject>Potassium</subject><subject>Pulmonology</subject><subject>Quality of life</subject><subject>Tumors</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkVtLxDAQhYMoKOu--QMCvihYTRPbpC_CUrws1FW8PIdsMl2j3USTdmH_vd0Lor7MDMw3hzkchI5Scs55VlzoLkAXz2nBRL6DDmiai0Sk4nL317yPhjG-E0JSwinh5AB9lY11VqsGV2rqg2p9WOIniF3TRqwifgx-5ny0Ed-r8AEBW4dHZqGcBoOfWzUDPPEuiXPVNLiEvlSdm-FyBQR8Mnkuq_J0dTR2xjuIVh2ivVo1EYbbPkCvN9cv5V1SPdyOy1GVaMrzNtFFDaQ2gumaM6LAUGKAUMFVYUxeMwEGsjTVwpCCZiszhovMCMKEmYqcsgG62uh-dtM5GA2uDaqRn8HOVVhKr6z8u3H2Tc78QhaZyNha4GQrEPxXB7GVcxt1b1E58F2UtP-Lpes6QMf_0HffBdfbW1OXBcty3lNnG0oHH2OA-ueZlMhVhnKToVxnyL4ByfGQ0A</recordid><startdate>20220920</startdate><enddate>20220920</enddate><creator>Hanafi, Arif R</creator><creator>Jayusman, Achmad M</creator><creator>Sutandyo, Noorwati</creator><creator>Kurniawati, Sri</creator><creator>Setiawan, Lyana</creator><creator>Diandra, Alyssa</creator><creator>Hidayat, Kusmantoro</creator><general>Cureus Inc</general><general>Cureus</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220920</creationdate><title>Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia</title><author>Hanafi, Arif R ; Jayusman, Achmad M ; Sutandyo, Noorwati ; Kurniawati, Sri ; Setiawan, Lyana ; Diandra, Alyssa ; Hidayat, Kusmantoro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c276t-c9fe0fd83cf730aed20de0287a9dd6f38ede511c8d09252070d785d8038db8623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anemia</topic><topic>Antigens</topic><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Creatinine</topic><topic>Electrolytes</topic><topic>Growth factors</topic><topic>Hemoglobin</topic><topic>Hyponatremia</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Laboratories</topic><topic>Lung cancer</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>Medical records</topic><topic>Mortality</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Patients</topic><topic>Potassium</topic><topic>Pulmonology</topic><topic>Quality of life</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hanafi, Arif R</creatorcontrib><creatorcontrib>Jayusman, Achmad M</creatorcontrib><creatorcontrib>Sutandyo, Noorwati</creatorcontrib><creatorcontrib>Kurniawati, Sri</creatorcontrib><creatorcontrib>Setiawan, Lyana</creatorcontrib><creatorcontrib>Diandra, Alyssa</creatorcontrib><creatorcontrib>Hidayat, Kusmantoro</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hanafi, Arif R</au><au>Jayusman, Achmad M</au><au>Sutandyo, Noorwati</au><au>Kurniawati, Sri</au><au>Setiawan, Lyana</au><au>Diandra, Alyssa</au><au>Hidayat, Kusmantoro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><date>2022-09-20</date><risdate>2022</risdate><volume>14</volume><issue>9</issue><spage>e29386</spage><epage>e29386</epage><pages>e29386-e29386</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Background: Lung cancer is the most common cause of cancer-related death among men in the world. Given the very high mortality caused by lung cancer, a biological marker to determine a more sensitive therapy among non-small cell lung cancer (NSCLC) patients is needed. This study aims to demonstrate that the clinical laboratory result can be a prognosis marker in NSCLC patients in Indonesia.Methods: This study was a retrospective cohort study. The sample was obtained from the patient's serum and the examined routine blood test (hemoglobin, leukocyte, platelets), hemostasis (fibrinogen and D-dimers), blood chemistry test (aspartate transaminase [AST], alanine transaminase [ALT], albumin, urea, creatinine, and blood glucose), electrolyte (sodium, potassium, chloride, and calcium) and tumor markers (carcinoembryonic antigen [CEA] and Cyfra 21-1). Data were analyzed and interpreted using SPSS (IBM Corp., Armonk, NY, USA). Analysis of the data was done to find the survival rate of sociodemographic variables, clinicopathologic variables, and clinic laboratory variables.Results: The study findings showed statistically significant results that were poor prognosis for these following conditions: performance status (PS) 3-4 median survival (MS):26 days, p=&lt;0.001; TNM stage IVb MS:58 days, p=0.001; high leukocyte MS:69 days, p=0.018; low platelet MS:50 days, p=0.013; high D-dimer MS:69 days, p=0.020; low albumin MS:56 days, p=0.001; high sodium MS:15 days, low sodium MS:50 days, p=&lt;0.001; high chloride MS:15 days, low chloride MS:27 days, p=&lt;0.001.Conclusion: In the advanced stage NSCLC, these findings indicate poorer prognoses; PS 3-4, IVb clinical stage, leukocytosis, thrombocytopenia, hyper-coagulopathy, hypoalbuminemia, hyper-hyponatremia, and hyper-hypochloremia. Further studies regarding the correlation between clinical laboratory and survival rate are needed.</abstract><cop>Palo Alto</cop><pub>Cureus Inc</pub><doi>10.7759/cureus.29386</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Curēus (Palo Alto, CA), 2022-09, Vol.14 (9), p.e29386-e29386
issn 2168-8184
2168-8184
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9585362
source Publicly Available Content Database; PubMed Central
subjects Anemia
Antigens
Biomarkers
Cancer therapies
Creatinine
Electrolytes
Growth factors
Hemoglobin
Hyponatremia
Internal Medicine
Kinases
Laboratories
Lung cancer
Medical diagnosis
Medical prognosis
Medical records
Mortality
Mutation
Oncology
Pathology
Patients
Potassium
Pulmonology
Quality of life
Tumors
title Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T09%3A41%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Laboratory%20Results%20as%20Prognosis%20Marker%20in%20Advanced%20Stage%20Non-small%20Cell%20Lung%20Cancer%20(NSCLC)%20in%20Indonesia&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Hanafi,%20Arif%20R&rft.date=2022-09-20&rft.volume=14&rft.issue=9&rft.spage=e29386&rft.epage=e29386&rft.pages=e29386-e29386&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.29386&rft_dat=%3Cproquest_pubme%3E2730312730%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c276t-c9fe0fd83cf730aed20de0287a9dd6f38ede511c8d09252070d785d8038db8623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2730493567&rft_id=info:pmid/&rfr_iscdi=true